These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 24462697)

  • 1. Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model.
    Smither SJ; Eastaugh LS; Steward JA; Nelson M; Lenk RP; Lever MS
    Antiviral Res; 2014 Apr; 104():153-5. PubMed ID: 24462697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model.
    Oestereich L; Lüdtke A; Wurr S; Rieger T; Muñoz-Fontela C; Günther S
    Antiviral Res; 2014 May; 105():17-21. PubMed ID: 24583123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus.
    Bixler SL; Bocan TM; Wells J; Wetzel KS; Van Tongeren SA; Dong L; Garza NL; Donnelly G; Cazares LH; Nuss J; Soloveva V; Koistinen KA; Welch L; Epstein C; Liang LF; Giesing D; Lenk R; Bavari S; Warren TK
    Antiviral Res; 2018 Mar; 151():97-104. PubMed ID: 29289666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ebola virus dynamics in mice treated with favipiravir.
    Madelain V; Oestereich L; Graw F; Nguyen TH; de Lamballerie X; Mentré F; Günther S; Guedj J
    Antiviral Res; 2015 Nov; 123():70-7. PubMed ID: 26343011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose regimen of favipiravir for Ebola virus disease.
    Mentré F; Taburet AM; Guedj J; Anglaret X; Keïta S; de Lamballerie X; Malvy D
    Lancet Infect Dis; 2015 Feb; 15(2):150-1. PubMed ID: 25435054
    [No Abstract]   [Full Text] [Related]  

  • 6. Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques.
    Guedj J; Piorkowski G; Jacquot F; Madelain V; Nguyen THT; Rodallec A; Gunther S; Carbonnelle C; Mentré F; Raoul H; de Lamballerie X
    PLoS Med; 2018 Mar; 15(3):e1002535. PubMed ID: 29584730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of Marburg virus with orally administrated T-705 (Favipiravir) in a mouse model.
    Zhu W; Zhang Z; He S; Wong G; Banadyga L; Qiu X
    Antiviral Res; 2018 Mar; 151():39-49. PubMed ID: 29369776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Routes of Administration, Frequency, and Duration of Favipiravir Treatment in Mouse and Guinea Pig Models of Ebola Virus Disease.
    Johnson DM; Juelich T; Zhang L; Smith JK; Kalveram BK; Perez D; Smith J; Grimes MR; Garron T; Torres M; Massey S; Brasel T; Beasley DWC; Freiberg AN; Comer JE
    Viruses; 2024 Jul; 16(7):. PubMed ID: 39066263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with Ebola virus.
    Bixler SL; Bocan TM; Wells J; Wetzel KS; Van Tongeren SA; Garza NL; Donnelly G; Cazares LH; Soloveva V; Welch L; Epstein C; Liang LF; Giesing D; Lenk R; Bavari S; Warren TK
    Antiviral Res; 2018 Mar; 151():50-54. PubMed ID: 29289664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials.
    Madelain V; Mentré F; Baize S; Anglaret X; Laouénan C; Oestereich L; Nguyen THT; Malvy D; Piorkowski G; Graw F; Günther S; Raoul H; de Lamballerie X; Guedj J
    CPT Pharmacometrics Syst Pharmacol; 2020 May; 9(5):258-271. PubMed ID: 32198838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ribavirin does not potentiate favipiravir antiviral activity against Ebola virus in non-human primates.
    Madelain V; Duthey A; Mentré F; Jacquot F; Solas C; Lacarelle B; Vallvé A; Barron S; Barrot L; Mundweiler S; Thomas D; Carbonnelle C; Raoul H; de Lamballerie X; Guedj J
    Antiviral Res; 2020 May; 177():104758. PubMed ID: 32135218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.
    Nguyen TH; Guedj J; Anglaret X; Laouénan C; Madelain V; Taburet AM; Baize S; Sissoko D; Pastorino B; Rodallec A; Piorkowski G; Carazo S; Conde MN; Gala JL; Bore JA; Carbonnelle C; Jacquot F; Raoul H; Malvy D; de Lamballerie X; Mentré F;
    PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005389. PubMed ID: 28231247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Filovirus Virulence in Interferon α/β and γ Double Knockout Mice, and Treatment with Favipiravir.
    Comer JE; Escaffre O; Neef N; Brasel T; Juelich TL; Smith JK; Smith J; Kalveram B; Perez DD; Massey S; Zhang L; Freiberg AN
    Viruses; 2019 Feb; 11(2):. PubMed ID: 30717492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent progress on the treatment of Ebola virus disease with Favipiravir and other related strategies.
    Zhang T; Zhai M; Ji J; Zhang J; Tian Y; Liu X
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2364-2368. PubMed ID: 28462833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recent Advances in Vaccines and Drugs Against the Ebola Virus].
    Zhu X; Yao C; Wei Y; Kou Z; Hu K
    Bing Du Xue Bao; 2015 May; 31(3):287-92. PubMed ID: 26470536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks.
    Haque A; Hober D; Blondiaux J
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5892-902. PubMed ID: 26248374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Favipiravir: a new medication for the Ebola virus disease pandemic.
    Nagata T; Lefor AK; Hasegawa M; Ishii M
    Disaster Med Public Health Prep; 2015 Feb; 9(1):79-81. PubMed ID: 25544306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies.
    Madelain V; Baize S; Jacquot F; Reynard S; Fizet A; Barron S; Solas C; Lacarelle B; Carbonnelle C; Mentré F; Raoul H; de Lamballerie X; Guedj J
    Nat Commun; 2018 Oct; 9(1):4013. PubMed ID: 30275474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Marburg and Ebola hemorrhagic fevers--pathogens, epidemiology and therapy].
    Stock I
    Med Monatsschr Pharm; 2014 Sep; 37(9):324-30; quiz 331-2. PubMed ID: 25282746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Lassa virus and Ebola virus infection in host cells treated with the kinase inhibitors genistein and tyrphostin.
    Kolokoltsov AA; Adhikary S; Garver J; Johnson L; Davey RA; Vela EM
    Arch Virol; 2012 Jan; 157(1):121-7. PubMed ID: 21947546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.